Telix's FDA-Approved Brain Cancer Imaging Drug Now Administered to First US Patients

Telix Pharmaceuticals has begun administering its FDA-approved imaging drug, Pixclara® (floretyrosine F 18), to patients in the United States. This amino acid PET drug is designed to help physicians differentiate recurrent or progressive glioma from treatment-related changes in both adult and pediatric brain cancer patients, marking its commercial availability and offering a new diagnostic tool.